While Indian pharmaceutical majors continue to face severe pricing pressure in the US market, Africa has been a growth story. However, Indian companies are now facing headwinds here, too, especially in the institutional sales or tender business.
In the listed space, five major companies — Cipla, Aurobindo, Strides Sashun, Ipca Labs and Ajanta Pharma — cater to the anti-malarial and anti-retroviral (ARV) tender business. Sales for this segment came down significantly in the March quarter and in 2017-18. Delay, funding cuts for organisations such as the Global Fund and ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Tue, June 05 2018. 00:37 IST
